Clinical Omics – News and Features

At a recent London Proteomics Discussion Group Meeting, Professor Roman Fischer kicked off the event by addressing the apparent "failure" of proteomics to deliver new clinical biomarkers thus far. Technology Networks sat down with Fischer to discuss spatial proteomics, and to expand on some of the key aspects of his research.

In this article, we explore the two principal tracks that are used to identify and characterize proteins by mass spectrometry – "bottom-up" and "top-down" proteomics.

Researchers have identified 27 proteins that are present at different levels in the blood of COVID-19 patients, depending on the severity of their symptoms.

A global coalition involving over 500 scientists, known as the COVID-19 MS Coalition, was announced earlier this week. The coalition aims to share mass spectrometry data on COVID-19 for the purpose of novel biomarker discovery and understanding the infection more deeply at a molecular level. Technology Networks spoke with Perdita Barran to find out more.

Researchers have found 27 potential biomarkers that are present in different levels in patients with COVID-19, depending on the severity of their symptoms. The markers could help doctors to predict how ill a patient will become and provide scientists with new targets for drug development.

Jagannath Swaminathan is the co-founder of Erisyon and a researcher at the Marcotte Lab at the University of Texas Austin. In this interview, we discuss the concept of next-generation protein sequencing, clinical proteomics and the critical role of protein sequencing in the fight against COVID-19.

To learn more about some of the ways that companion diagnostics can benefit oncology patients, Technology Networks spoke to Dr Luca Quagliata, Global Director of Medical Affairs for Clinical NGS and Oncology at Thermo Fisher Scientific.

Targeted proteomics start-up ProteiQ Biosciences recently announced the launch of InfineQ, its cloud-based solution software for near real-time processing of proteomics data. Technology Networks spoke with Arnoud Groen, CSO and co-founder of ProteiQ, to learn more about the solution and how it provides the scale and speed required for biomarker discovery.

Scientists have developed the first blood test that can accurately detect more than 50 different types of cancer. It can also identify in which tissue the cancer originated, often before any clinical signs or symptoms of the disease present.

Clinical trials produce a massive amount of medically relevant and highly sensitive data. Leveraging such data could make a difference to efforts to create more personalized, effective medicines. We talked to Medidata’s Sheila Diamond to find out more.